Nevirapina Teva (Nevirapine)

Nevirapine, the active ingredient in Nevirapina Teva, is a non‑nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It is employed in the management of HIV‑1 infection, typically as part of combination antiretroviral therapy in adults and adolescents.

GNH USA supplies Nevirapina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across multiple markets and adhering to stringent regulatory standards for reliable global distribution.

Nevirapina Teva is a non‑nucleoside reverse transcriptase inhibitor used in the treatment of HIV‑1 infection as part of combination antiretroviral regimens.

- HIV‑1 infection (treatment): reduces viral load and improves immune function when combined with other antiretrovirals. - HIV‑1 infection (prevention of mother‑to‑child transmission): lowers the risk of vertical transmission when administered during labor and postpartum. - HIV‑1 infection (treatment‑experienced patients): provides an alternative mechanism for patients with resistance to other drug classes.

Nevirapina Teva may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions that may be pruritic. - Nausea: transient gastrointestinal discomfort. - Fatigue: generalized tiredness. - Headache: mild to moderate intensity. - Insomnia: difficulty initiating or maintaining sleep. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe mucocutaneous reaction requiring immediate medical attention. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Severe hepatotoxicity: marked elevation of liver enzymes or liver failure. - Hypersensitivity reactions: systemic allergic response with fever and organ involvement. - Liver failure: acute loss of liver function. - Severe rash: extensive skin involvement beyond mild erythema.

Before initiating therapy with Nevirapina Teva, several safety considerations should be observed.

- Liver function monitoring: assess baseline and periodic liver enzymes due to risk of hepatotoxicity. - Pregnancy risk assessment: evaluate benefits versus potential fetal risks, as safety data are limited. - Concomitant hepatitis B or C infection: monitor closely for liver complications. - Prior hypersensitivity: avoid use in patients with known severe reactions to nevirapine. - Drug resistance testing: consider baseline resistance profiles to ensure efficacy. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Nevirapina Teva can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: may increase nevirapine concentrations and toxicity. - St. John's wort: induces metabolism, reducing nevirapine effectiveness. - Carbamazepine: strong enzyme inducer that lowers nevirapine levels.

Moderate Interactions (Monitor Closely): - Efavirenz: may affect plasma levels of both agents. - Zidovudine: combined use can increase risk of hematologic toxicity. - Lamivudine: monitor for additive hepatic effects.